Experience

Aquinnah Pharmaceuticals

• United States
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist

  • May 2023 - Present



Vesigen Therapeutics, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Scientist II Drug Discovery (Neuroscience)

  • May 2022 - May 2023

  Vesigen recognizes the need to develop more sophisticated packaging for therapeutic agents to enable direct transfer to targets, while avoiding immune reaction and internal degradation mechanisms that interfere with successful delivery. This treatment gap drives Vesigen’s development of our novel ARMMs (ARRDC1 Mediated Microvesicles) technology, a class of fusogenic extracellular vesicles that is enabling new therapies to address unmet medical needs. Vesigen recognizes the need to develop more sophisticated packaging for therapeutic agents to enable direct transfer to targets, while avoiding immune reaction and internal degradation mechanisms that interfere with successful delivery. This treatment gap drives Vesigen’s development of our novel ARMMs (ARRDC1 Mediated Microvesicles) technology, a class of fusogenic extracellular vesicles that is enabling new therapies to address unmet medical needs.



University of Guelph

• Canada
• Higher Education
• 700 & Above Employee

• • Sep 2021 - May 2022

  Two general categories of cellular aberrations have been identified in Parkinson’s Disease neurons. The first involves protein misfolding, aggregation and proteostasis. The second centers on mitochondrial damage and oxidative/nitrosative stress. A major obstacle in the Parkinson’s Disease field has been the identification of key cellular targets or pathways that connect these cellular dysfunctions. The Ryan lab has capitalized on recent advances in hiPSC technology that allowed for the development of a patient derived stem cell models of Parkinson’s Disease for mechanistic study. Using these model systems, we aim to gain a better understanding of the molecular deficits that result in neuronal impairment by focusing on mitochondrial function and oxidative stress. Show less

• • Oct 2016 - Sep 2021



University of Calgary

• Canada
• Higher Education
• 700 & Above Employee

• Masters Student

  • Apr 2013 - Jul 2016

  In the Biernaskie lab, I helped to characterized the Schwann cell profile during development and following injury. I further explored the potential of skin-derived precursor Schwann cells (SKPSCs) as an accessible and autologous source of glia cells to enhance nerve regeneration following peripheral nerve injury. In the Biernaskie lab, I helped to characterized the Schwann cell profile during development and following injury. I further explored the potential of skin-derived precursor Schwann cells (SKPSCs) as an accessible and autologous source of glia cells to enhance nerve regeneration following peripheral nerve injury.